What serious side effects can spaxentan cause?

spasintan

Sparsentan/sparsentan is a single molecule with endothelin type A receptor (ETAR) and angiotensin II type 1 receptor (ATIR) antagonism. It has high affinity for ETAR and AT1R. Endothelin-1 and angiotensin II are considered to be involved in the pathogenesis of IgAN through ETAR and AT1R respectively.

Reduces proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for rapid disease progression.

Sparsentine's Serious

1. Hypotension: In a clinical trial, patients receiving sparsentan had a higher incidence of hypotension than patients in the irbesartan group, and some patients had more severe hypotension.

2. Acute kidney injury: Drugs that inhibit the renin-angiotensin system can cause acute kidney injury. Patients whose renal function may partially depend on the activity of the renin-angiotensin system may be particularly susceptible to acute kidney injury during sparsentan treatment.

3. Hyperkalemia: Patients with end-stage renal disease or who are taking drugs that increase potassium are at increased risk of developing hyperkalemia during treatment with sparsentane.

4. Body fluid retention: Endothelin receptor antagonists may cause body fluid retention, which has been observed in clinical studies of FILSPARI.

How to deal with serious side effects of sparsentan

1. Hypotension: For patients at risk of hypotension, consider adjusting antihypertensive drugs to maintain an appropriate state. When blood pressure decreases, even if other antihypertensive drugs have been discontinued or reduced, consider reducing the dose or stopping sparsentan until the blood pressure stabilizes before continuing to take it.

2. Acute kidney injury: Monitor renal function regularly. For patients who experience clinical decline in renal function while taking sparsentan, suspension or discontinuation of sparsentan treatment should be considered.

3. Hyperkalemia: Regularly monitor the patient's serum potassium and perform appropriate treatment, such as using diuretics to promote urinary excretion, thereby reducing the concentration of potassium ions. At the same time, it may be necessary to reduce the dose or discontinue sparsentan.

4. Fluid retention: If clinically significant fluid retention occurs, the cause should be determined promptly, and diuretic treatment should be initiated or the dose of sparsentan should be adjusted.

Patients who experience the above serious side effects should consult a doctor immediately for appropriate treatment to avoid further aggravation of side effects and affecting their health.

Recommended related articles: